Healthcare Triangle's Q2 revenue jumps 158% to $9.2M, but losses widen and cash dwindles to $1.9M
HCTI sits 61% above its 52-week low of $1 on elevated volume (47× avg).
Summary
Healthcare Triangle reported Q2 revenue of $9.2M (up 158% YoY) but a net loss of $4.4M and cash of just $1.9M. Subsequent events include 12.5M shares issued for acquisitions and a new $23.5M LOI.
Key Events · Earnings and Guidance · HCTI
-
Revenue Surges 158% to $9.2M
Q2 2026 revenue reached $9.19M, up from $3.56M in Q2 2025, driven entirely by the newly acquired Customer Engagement Services segment which contributed $6.31M.
-
Net Loss Widens to $4.4M
Net loss for Q2 2026 was $4.42M, compared to $1.37M in Q2 2025. Operating expenses more than tripled to $6.14M, including $4.82M in general and administrative costs.
-
Cash Position Drops to $1.9M
Cash and cash equivalents fell to $1.91M as of June 30, 2026, from $7.63M at year-end 2025. Management cites a $50M equity line and ATM facility as sufficient for 12 months.
-
Massive Dilution from Subsequent Share Issuances
After June 30, 2026, the company issued 9.72M shares for the Teyame acquisition and 2.83M shares to SecureKloud, plus 350,000 shares under the ELOC for $314K net proceeds.
Analysis · HCTI · Technology
Healthcare Triangle's Q2 2026 results show explosive revenue growth driven by the Teyame acquisition, but the company remains deeply unprofitable with a $4.4M quarterly loss and only $1.9M in cash. The balance sheet is propped up by a $50M equity line and ATM facility, which management cites as sufficient for 12 months. Subsequent events reveal massive share issuance — 9.7M shares for Teyame and 2.8M shares to SecureKloud — that will significantly dilute existing holders. The company also disclosed a non-binding LOI to acquire 51% of CosmoInnovations for $23.5M, adding further execution risk.
At the time of this filing, HCTI was trading at $1.61 on NASDAQ in the Technology sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $1.00 to $244.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.